MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
PR Newswire•15/10/2026•16:10 ET
1
Key Highlights
- ➤MiniMed (MMED) completes separation from Medtronic as an independent public company
- ➤Nine-member Board appointed, completing MiniMed’s post-separation governance transition
- ➤Amy Bricker and Timothy L. Main join Board effective immediately
- ➤Kevin E. Lofton remains Board chair as MiniMed begins independent operations
- ➤MiniMed targets integrated insulin delivery, glucose sensing, algorithms and software
Expert Statements
Que Dallara, Chief Executive Officer of MiniMed
“As an independent public company, MiniMed has a clear mission: reduce the burden of diabetes management and make integrated technology easier to access and use”
Que Dallara, Chief Executive Officer of MiniMed
“That requires a Board that understands healthcare access and patient needs, and can also help us execute across technology, commercial operations, manufacturing, finance and governance.”
Que Dallara, Chief Executive Officer of MiniMed
“Our directors bring that range of experience as we build a simpler, more dependable experience for people with diabetes.”
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company PR Newswire
Directors bring expertise across healthcare access, medtech, commercial and manufacturing operations and public-company governance as MiniMed begins its next chapter as an independent company focused on making every day a better day for people with diabetes.
Get started
Create a free account to read the full story.